BioSpace News Archive

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that it plans to host a conference call on Thursday, May 07, 2020, at 8:30 a.m. ET to discuss its first quarter financial results and recent operational highlights. Individuals may participate in the live call via telephone by dialin

The partnership combines artificial intelligence with comprehensive virtual trial services to bring novel insights to research

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Monday, May 11, 2020 at 8:30 a.m. EDT to report its financial results for the quarter ended March

Biotricity Inc. (OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, announced that Steve Salmon has joined its Board of Directors. Mr. Salmon will bring additional expertise in business development transactions, market development, finance, technology, and capital market. His most recent experience was as a Venture Capitalist for Latterell Venture Partners, where he managed a number of portfolio comp

AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has received Institutional Review Board (IRB) approval of its Phase 2 OPTION 2 clinical trial protocol to investigate MS1819 in cystic fibrosis (CF) patients with

BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported that it has accepted and implemented FDA-recommended modifications to the primary endpoint for the CardiAMP® Cell Therapy Heart Failure Trial and associated statistical analysis plan. The Agency proposed these modifications to support the potential for marketing approval for the therapy based o

Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that it will be presenting data from its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor (nivolumab) for the treatment of recurrent glioblastoma at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be conducted virtually from May 29-31, 2020. Poster Discussion Title: Controlled IL

- Partnership with NJPCA, which represents 23 community health centers in NJ, funded 5 telehealth pilots; programs serving as role models for centers across state - The Grant enabled NJ community health centers to quickly implement telehealth to maintain continuity of care for underserved communities, especially critical during the current COVID-19 pandemic

Progenity , a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the appointment of Troy Seelye as Chief Information Officer (CIO). Mr. Seelye will help to strengthen Progenity’s technology and data strategy, leading the development of key products and services designed to transform the customer experience. “Troy joins the Proge

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2020 financial results on Friday, May 8, 2020. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host